Virtual Screening

SBVS requires the 3D structure of the biological target, typically derived from X-ray crystallography, cryo-EM, or homology modeling. The process involves computationally docking each ligand into the target's binding pocket and evaluating the complementarity using a scoring function. This method excels at discovering novel chemotypes with no prior ligand knowledge. Key steps include:

• Binding pocket detection to define the search space
• Conformational sampling of ligand torsional degrees of freedom
• Pose ranking via force-field or knowledge-based scoring functions

LBVS is employed when the target's 3D structure is unknown. It uses the chemical and structural information from one or more known active ligands to search for similar molecules. Common techniques include pharmacophore modeling, which abstracts the essential 3D arrangement of steric and electronic features, and shape-based screening, which aligns molecules based on volumetric overlap. QSAR models predict activity from molecular descriptors. This approach is limited to identifying compounds similar to known actives and may miss entirely novel scaffolds.

Modern virtual screening leverages SE(3)-equivariant neural networks and diffusion models to overcome traditional limitations. Models like EquiBind perform direct binding pocket identification and ligand coordinate prediction in a single forward pass, bypassing exhaustive conformational sampling. DiffDock frames pose prediction as a generative reverse diffusion process over translational, rotational, and torsional degrees of freedom. These methods achieve orders-of-magnitude speedups while maintaining or exceeding the accuracy of traditional docking tools.

PCM is a machine learning paradigm that simultaneously uses descriptors from both the ligand chemical space and the target protein sequence space to predict bioactivity across a large interaction matrix. Unlike single-target QSAR, PCM trains on multiple targets and ligands jointly, enabling predictions for previously unseen drug-target pairs. This approach is foundational for polypharmacology profiling and target fishing, where a single molecule is screened against an entire proteome to identify both therapeutic targets and potential off-target liabilities.

The enrichment factor (EF) quantifies how many more known active compounds are identified in a top fraction of a ranked database compared to random selection. For example, an EF₁% of 20 means the method is 20 times better than random at finding actives in the top 1% of results. Validation requires a carefully constructed decoy set—presumed inactive molecules with physical properties matched to the actives to prevent artificial enrichment from property biases. Other key metrics include ROC AUC and Boltzmann-Enhanced Discrimination of ROC (BEDROC).

A critical post-screening triage step involves filtering out PAINS (Pan-Assay Interference Compounds). These are chemical substructures known to promiscuously interfere with biological assays through mechanisms such as covalent modification of proteins, redox cycling, or colloidal aggregation. PAINS produce false positive activity readouts that do not represent specific, drug-like binding. Computational filters flag compounds containing rhodanines, phenolic Mannich bases, toxoflavins, and other problematic warheads before resources are invested in experimental validation.